Fatty acids inhibit growth-factor-induced diacylglycerol kinase alpha activation in vascular smooth-muscle cells.
We have previously shown that unsaturated fatty acids amplify platelet-derived-growth-factor (PDGF)-induced protein kinase C (PKC) activation in vascular smooth-muscle cells (VSMCs). Diacylglycerol-induced PKC activation is normally terminated by diacylglycerol kinases (DGKs). We thus hypothesized that fatty acids act by inhibiting a DGK. Fractionation of VSMC extracts demonstrated that the DGK alpha isoform was the major DGK activity present. PDGF markedly increased the DGK activity of cultured cells. An inhibitor selective for the DGK alpha isoform, R59949 [3-[2-[4-(bis-(4-fluorophenyl)methylene]piperidin-1-yl)ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone], abolished the growth-factor-induced increase in DGK activity, but had little effect on basal activity. PDGF thus selectively activates DGKalpha. Epidermal growth factor and alpha-thrombin stimulated total DGK activity similarly to PDGF. Activation by epidermal growth factor was sensitive to R59949, again suggesting involvement of DGKalpha. However, the alpha-thrombin-induced activity was unaffected by this agent. Unsaturated fatty acids inhibited growth-factor-induced DGKalpha activation, but had no effect on basal activity. Fatty acids also amplified the PDGF-induced increase in cell diacylglycerol content. These results indicate that inhibition of DGKalpha contributes to fatty-acid-induced amplification of PKC activation. Increased levels of fatty acids in diabetes may thus contribute to chronic PKC activation associated with this disorder.
Du
X
X
Department of Medicine, Indiana University School of Medicine, Roudebush VA Medical Center (111-E), 1481 West Tenth Street, Indianapolis, IN 46202, USA.
Jiang
Y
Y
Qian
W
W
Lu
X
X
Walsh
J P
JP
D000818:Animals; D002339:Carotid Arteries / Q000201:enzymology; D002462:Cell Membrane / Q000201:enzymology; D002478:Cells, Cultured; D003600:Cytosol / Q000201:enzymology; D019852:Diacylglycerol Kinase / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D004926:Escherichia coli / Q000201:enzymology; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000378:metabolism; D007700:Kinetics; D009131:Muscle, Smooth, Vascular / Q000201:enzymology*; D019301:Oleic Acid / Q000494:pharmacology; D019308:Palmitic Acid / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D052999:Quinazolinones; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D013552:Swine; D013917:Thrombin / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D005230:Fatty Acids, Nonesterified; D007527:Isoenzymes; D010880:Piperidines; D010982:Platelet-Derived Growth Factor; D011799:Quinazolines; D052999:Quinazolinones; D011994:Recombinant Proteins; C058544:R 59949; D019301:Oleic Acid; D019308:Palmitic Acid; D004815:Epidermal Growth Factor; D019852:Diacylglycerol Kinase; D013917:Thrombin